NeoGenomics, Inc. NEO 深 滬
等待開盤 04-01 09:30:00 美东时间
7.42
+0.220
+3.06%
華盛通- 最 高7.57
- 今 開7.30
- 成交量 126.12万股
- 最 低 7.16
- 昨 收 7.20
- 總市值 9.63亿
- 52周最高 13.74
- 市盈率 靜 --
- 換手率 0.00%
- 52周最低 4.72
- 委 比 -76.22%
- 總股本 1.30亿
- 歷史最高 61.57
- 量 比 0.97
- 振 幅 5.69%
- 歷史最低 0.96
- 每 手 1
- 風險率 2.08%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Earnings Scheduled For March 19, 2026
Companies Reporting Before The Bell • Neuraxis (AMEX:NRXS) is projected to repo...
03-19 19:11
NeoGenomics Launched RaDaR ST, Circulating Tumor DNA Assay For Detecting Molecular Residual Disease
The company estimates that MRD represents a $20+ billion addressable market, growing at 30% annually, which we believe is less than 10% penetrated
02-25 20:15
美股大行评级 | 潜在涨幅243.25%！泰利克斯制药获花旗升目标价至22.5美元，维持"买入"评级
今日重点评级关注：花旗：维持Telix Pharmaceuticals"买入"评级，目标价从22美元升至22.5美元；摩根士丹利：维持Vir Biotechnology"超配"评级，目标价从20美元升至24美元
02-25 11:03
Piper Sandler Maintains Overweight on NeoGenomics, Raises Price Target to $13
Piper Sandler analyst David Westenberg maintains NeoGenomics (NASDAQ:NEO) with a Overweight and raises the price target from $12 to $13.
02-25 00:33
财报速睇 | NeoGenomics, Inc. 2025财年Q4营收1.90亿美元，同比增长10.5%；归母净利润亏损0.10亿美元，同比亏损缩窄33.3%
华盛资讯2月18日讯，NeoGenomics, Inc.公布2025财年Q4业绩，公司Q4营收1.90亿美元，同比增长10.5%，归母净利润亏损0.10亿美元，同比亏损缩窄33.3%。
02-18 02:43
NeoGenomics shares are trading lower. The company announced Q4 financial results and issued FY26 sales guidance.
NeoGenomics shares are trading lower. The company announced Q4 financial result...
02-18 01:46
NeoGenomics Earnings Report: Q4 Overview
The Q4 earnings report for NeoGenomics (NASDAQ:NEO) was released on Tuesday, Fe...
02-17 20:06
Earnings Scheduled For February 17, 2026
Companies Reporting Before The Bell • IDEAYA Biosciences (NASDAQ:IDYA) is likel...
02-17 19:11
Exploring NeoGenomics's Earnings Expectations
NeoGenomics (NASDAQ:NEO) is preparing to release its quarterly earnings on Tues...
02-17 02:01
美股大行评级 | Medline获14家大行首予评级，最高目标价52美元；富国银行上调GOOGL目标价从268美元升至350美元
今日重点评级关注：HC Wainwright & Co.：维持Enlivex Therapeutics"买入"评级，目标价从7美元升至13美元；BTIG：维持Oruka Therapeutics"买入"评级，目标价从63美元升至73美元
01-13 10:18
